| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cf32b60391b469c41e86c353437f5751 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4439
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39558
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-517
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-32 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4439
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-517 |
| filingDate |
2011-11-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bc0893324b4ae6ba1b449a7867d174dc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a02521f8177d3d9db10b12604c10805b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e4d8a1c2b5b08147b4ce4b355b593e94
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d4bfdb6458168837acd1b82ac73ed0c2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d8a0b4db8bd4bba87bfd6c8c23fb9372 |
| publicationDate |
2013-12-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20130143582-A |
| titleOfInvention |
Use of 2-carboxamide cycloamino urea derivatives in the treatment of EVF-dependent diseases or disorders that have acquired resistance to agents targeting members of the EVF family |
| abstract |
Use of a compound of formula (I) in the treatment of epidermal growth factor receptor (EGFR) dependent disease or a disease that has acquired resistance to agents targeting EGFR family members, the compound for the manufacture of a pharmaceutical composition for treating the disease Use of, a combination of said compound with an EGFR modulator for said use, a method of treating said disease with said compound, and a pharmaceutical for the treatment of said disease comprising said compound alone or in particular with an EGFR modulator. Formulation. (I) |
| priorityDate |
2010-11-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |